T
Thomas Powles
Researcher at Queen Mary University of London
Publications - 804
Citations - 57482
Thomas Powles is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 82, co-authored 655 publications receiving 39271 citations. Previous affiliations of Thomas Powles include Charing Cross Hospital & University of London.
Papers
More filters
Journal ArticleDOI
LBA5CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
Bernard Escudier,Nizar M. Tannir,David F. McDermott,O.A. Frontera,Bohuslav Melichar,Elizabeth R. Plimack,Philippe Barthélémy,Saby George,Victoria Neiman,C. Porta,Toni K. Choueiri,Thomas Powles,Frede Donskov,P. Salman,Christian K. Kollmannsberger,Brian I. Rini,Sabeen Mekan,M.B. McHenry,Hans J. Hammers,Robert J. Motzer +19 more
Journal ArticleDOI
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Thomas Powles,Mark R. Lackner,Stéphane Oudard,Bernard Escudier,Christy Ralph,Janet E. Brown,Robert E. Hawkins,Daniel Castellano,Brian I. Rini,Michael Staehler,Alain Ravaud,Wei Lin,Bridget O'Keeffe,Yulei Wang,Shan Lu,Jill M. Spoerke,Ling Huw,Michelle Byrtek,Rui Zhu,Joseph A. Ware,Robert J. Motzer +20 more
TL;DR: It is demonstrated that dual PI3K/mTOR inhibition by apitolisib was less effective than was everolimus in mRCC, likely because full blockade of PI3k/m TOR signaling resulted in multiple on-target adverse events.
Journal ArticleDOI
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Matthew D. Galsky,Noah M. Hahn,Thomas Powles,Beth A. Hellerstedt,Seth P. Lerner,Thomas A. Gardner,Menggang Yu,Mark Allen O'Rourke,Nicholas J. Vogelzang,Darren M. Kocs,Scott A. McKenney,Anton Melnyk,Thomas E. Hutson,Mary A. Rauch,Yunfei Wang,Lina Asmar,Guru Sonpavde,Guru Sonpavde +17 more
TL;DR: Delivery of GCS was hampered by excessive toxicity in both advanced and neoadjuvant settings, and the trial was closed.
Journal ArticleDOI
Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus
Michael Lardas,Fiona Stewart,Duncan Scrimgeour,Fabian Hofmann,Lorenzo Marconi,Saeed Dabestani,Axel Bex,Alessandro Volpe,Steven E. Canfield,Michael Staehler,Milan Hora,Thomas Powles,Axel S. Merseburger,Markus A. Kuczyk,Karim Bensalah,Peter F.A. Mulders,Börje Ljungberg,Thomas B. Lam,Thomas B. Lam +18 more
TL;DR: The evidence base, although derived from retrospective case series and complemented by expert opinion, suggests that patients with nonmetastatic RCC and VCT and acceptable performance status should be considered for surgical intervention.
Journal ArticleDOI
Cannabis-induced cytotoxicity in leukemic cell lines : The role of the cannabinoid receptors and the MAPK pathway
Thomas Powles,Robert te Poele,Jonathan Shamash,Tracy Chaplin,David Propper,Simon P. Joel,Tim Oliver,Wai M. Liu +7 more
TL;DR: One of the most intriguing findings was that THC-induced cell death was preceded by significant changes in the expression of genes involved in the mitogen-activated protein kinase (MAPK) signal transduction pathways.